Nomura Holdings Inc vs DENTSPLY SIRONA Inc — how do they compare? Nomura Holdings Inc trades at $9.5 (market cap $27.55B), while DENTSPLY SIRONA Inc trades at $8.79 (market cap $1.73B). The key difference: Nomura Holdings Inc is far larger — about 15.9× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| NMR | XRAY | |
|---|---|---|
Market Cap | $27.55B | $1.73B |
Volume | 782,470 | 6,198,582 |
Sector | Financials | Health |
52-Week High | $10.86 | $14.68 |
52-Week Low | $6.73 | $8.52 |
Typical Hold Time | 55 Days | 72 Days |
Enterprise Value | $38.54T | $3.80B |
Dividend Yield | 3.4% | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.33 and P/B of 1.15. Analyst sentiment is cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
The outlook remains balanced - attractive valuation and revenue growth potential are offset by cash flow challenges and technical weakness. Key risks include Japan's fiscal policy impacts on bond markets and sustained negative operating cash flow. Investors should weigh the discounted valuation against execution risks in the current macroeconomic environment.
DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →